Patents Assigned to INSERM (Institut National de la Santé et de la Recherche Médicale)
-
Patent number: 11559244Abstract: Disclosed is a method for the generation of a consciousness indicator for a non-communicating subject, including the steps of generating an auditory stimulation, receiving an electrocardiographic signal of the subject obtained from a recording during the generation of the auditory stimulation, extracting at least one feature from the electrocardiographic signal and deducing a consciousness indicator from an analysis of the electrocardiographic feature.Type: GrantFiled: September 11, 2018Date of Patent: January 24, 2023Assignees: ICM—INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CNRS (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE), APHP, SORBONNE UNIVERSITÉInventors: Federico Raimondo, Jacobo D Sitt, Lionel Naccache, Diego Fernandez Slezak
-
Patent number: 11559566Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.Type: GrantFiled: July 10, 2020Date of Patent: January 24, 2023Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, SORBONNE UNIVERSITEInventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
-
Publication number: 20230021272Abstract: A vibrotactile stimulation device intended to be applied against a body medium (MC) to be stimulated, produced in the form of a functional unit, comprising a vibrating effector suitable for applying, to said medium, pulses of mechanical vibrational energy, and a controller for controlling the effector according to stimulation rules. The functional unit further houses a first electrode suitable for cooperating with at least one second electrode separated from the first electrode in order to supply signals representative of a cardiac activity and a muscular activity on the medium to be stimulated, said controller being sensitive to cardiac activity and muscular activity signals in order to influence the stimulation. The stimulation device may be used for body stimulation in combating sleep apnea, with improved detection.Type: ApplicationFiled: September 29, 2022Publication date: January 19, 2023Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE RENNES IInventor: Alfredo HERNANDEZ
-
Publication number: 20220411493Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.Type: ApplicationFiled: April 29, 2022Publication date: December 29, 2022Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de StrasbourgInventors: Thomas BAUMERT, Rajeevkumar Tawar
-
Patent number: 11530241Abstract: The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.Type: GrantFiled: December 14, 2018Date of Patent: December 20, 2022Assignees: UNIVERSITE DE STRASBOURG, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALEInventor: Vincent Marion
-
Publication number: 20220396773Abstract: A method of obtaining 3D cell structures including differentiated human hepatic cells. The method includes: a first step of culturing stem cell-derived or immortalized human hepatic progenitors in a non-adherent culture vessel, preferably a low or ultra-low attachment culture vessel; a second step of transferring the stem cell-derived or immortalized human hepatic progenitors to a culture medium including methacrylated gelatin (GelMa), thereby embedding the stem cell-derived or immortalized human hepatic progenitors in a GelMa matrix; and a third step of covering the GelMa matrix with culture medium and culturing the stem cell-derived or immortalized human hepatic progenitors embedded in the GelMa matrix, thereby obtaining 3D cell structures including differentiated human hepatic cells. Also, methods for engineering an artificial liver model or an artificial liver organ, and for assessing in vitro the metabolism, toxicity and/or therapeutic effects of a compound.Type: ApplicationFiled: November 13, 2020Publication date: December 15, 2022Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE RENNES 1, ÉCOLE DES HAUTES ÉTUDES EN SANTÉ PUBLIQUE (EHESP)Inventors: Georges BAFFET, Marie CUVELLIER, Frédéric EZAN, Sophie ROSE
-
Patent number: 11525008Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of lung cancer. The inventors showed that FHIT (also known as bis(5-adenosyl)-triphosphatase) regulates HER2 activity in lung tumor cells and that HER2 inhibitors reduce invasion induced by FHIT inhibition. In particular, the present invention relates to a method of treating lung cancer in a patient in need thereof comprising the steps of i) determining the expression level of FHIT in a tumor tissue sample obtained from the patient, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering to the patient a therapeutically effective amount of at least one HER2 inhibitor when the expression level determined at step i) is lower than the predetermined reference level.Type: GrantFiled: September 21, 2017Date of Patent: December 13, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE REIMS CHAMPAGNE-ARDENNE, CENTRE HOSPITALIER UNIVERSITAIRE DE REIMSInventors: Béatrice Raby, Amina Jouida, Myriam Polette
-
Patent number: 11511016Abstract: The present invention relates to a method for preparing a porous scaffold for tissue engineering. It is another object of the present invention to provide a porous scaffold obtainable by the method as above described, and its use for tissue engineering, cell culture and cell delivery. The method of the invention comprises the steps consisting of: a) preparing an alkaline aqueous solution comprising an amount of at least one polysaccharide, an amount of a cross-linking agent and an amount of a porogen agent b) transforming the solution into a hydrogel by placing said solution at a temperature from about 4° C. to about 80° C. for a sufficient time to allow the cross-linking of said amount of polysaccharide and c) submerging said hydrogel into an aqueous solution d) washing the porous scaffold obtained at step c).Type: GrantFiled: March 25, 2019Date of Patent: November 29, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris CitéInventors: Catherine Le Visage, Didier Letourneur
-
Patent number: 11504094Abstract: An apparatus and a method for contrast-enhanced ultrasound (CEUS) including use of a fluid dynamics model for the analysis of dynamic contrast-enhanced ultrasound (DCEUS).Type: GrantFiled: July 27, 2018Date of Patent: November 22, 2022Assignees: (INSERM) INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ DE TOURS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE BORDEAUX, INSTITUT POLYTECHNIQUE DE BORDEAUX (IPB)Inventors: Baudouin Denis de Senneville, Franck Perrotin, Jean-Michel Escoffre, Ayache Bouakaz
-
Publication number: 20220361896Abstract: A medical device for penetrating a bone structure including a processing unit having a transfer function that associates an electrical conductivity value S with a depth value d, wherein the processing unit is configured to detect a threshold selected from amongst an absolute threshold, a relative threshold and a critical gradient, and to emit a warning signal and/or control signal responsive to detection of the threshold.Type: ApplicationFiled: May 2, 2022Publication date: November 17, 2022Applicants: SpineGuard, Sorbonne Universite, Centre National de la Recherche Scientifique - CNRS, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Stephane BETTE, Jimmy DA SILVA, Thibault CHANDANSON, Guillaume MOREL, Maurice BOURLION
-
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
Patent number: 11499154Abstract: The present invention concerns the use of antisense oligonucleotides (AON) capable of inhibiting expression of dynamin 2, advantageously human dynamin 2, for use in the treatment of Charcot-Marie-Tooth disease (CMT) and centronuclear myopathies (CNM).Type: GrantFiled: April 10, 2018Date of Patent: November 15, 2022Assignees: GENETHON, UNIVERSITE D'EVRY-VAL-D'ESSONNE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventor: Ana Maria Buj Bello -
Patent number: 11484537Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.Type: GrantFiled: February 20, 2019Date of Patent: November 1, 2022Assignees: AELIS FARMA, INSERM (Institut National de la Santé et de la Recherche Médicale), UNIVERSITE DE BORDEAUXInventors: Pier Vincenzo Piazza, Sandy Fabre, Mathilde Metna, Stéphanie Monlezun, Arnau Busquet-Garcia, Daniela Cota, Giovanni Marsicano, Jean-Michel Revest, Monique Vallée
-
Patent number: 11484577Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.Type: GrantFiled: February 14, 2017Date of Patent: November 1, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Philippe Valet, Cedric Dray, Vincent Minville, Bernard Frances, Francois Labaste, Claire Vinel
-
Patent number: 11479817Abstract: The present invention relates to a method for discriminating an operationally tolerant (TOL) subject from a non-operationally tolerant (STA) subject, comprising the following steps: i) establishing a composite score of tolerance (cSoT) with the expression levels of six genes in a biological sample obtained from said subject and two clinical parameters; wherein said six genes are ID3, AKR1C3, CD40, CTLA4, TCL1A and MZB1, and wherein said cSoT is established by the following formula: cSoT = ? i n ? = ? i × Exprs + ? test ? ? time × age test ? ? time + ? trans ? ? time × age trans ? ? time + intercept - scaling ? ? coefficient ii) comparing this cSoT with a predetermined reference value; and iii) concluding that the subject is TOL when the cSoT is higher than the predetermined reference value or concluding that the subject is STA when the cSoT is lower than the predetermined reference value.Type: GrantFiled: July 21, 2017Date of Patent: October 25, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Université de Nantes, Centre Hospitalier Universitaire de Nantes, Centre National de la Recherche ScientifiqueInventors: Richard Danger, Sophie Brouard, Magali Giral, Gérard Ramstein
-
Patent number: 11473145Abstract: The inventors initially participated to the identification of LPIN1 mutations as a cause for massive rhabdomyolysis episodes in children, triggered by febrile illness. The inventors have suggested that TLR9 antagonists would be suitable for the treatment of rhabdomyolysis (WO2017085115). The inventors thus treated 2 patients with lipin-1 disease by a TRL9 antagonist (hydroxychloroquine). They showed that the accumulation of mtDNA in plasma of the two patients before treatment decreases under treatment. When the treatment was stopped, the accumulation of mtDNA reappeared, then normalized when treatment was resumed. Accordingly, the present invention relates to a method for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist comprising determining the amount of mitochondrial DNA (mtDNA) in a blood sample obtained from the patient (e.g. by PCR).Type: GrantFiled: July 26, 2018Date of Patent: October 18, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), FOUNDATION IMAGING, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE PARISInventors: Pascale De Lonlay-Debeney, Peter Van Endert, Marine Madrange, Yamina Hamel, François-Xavier Mauvais
-
Patent number: 11472844Abstract: The invention relates to a peptidomimetic comprising or consisting of a D amino-acid sequence having at least 75% identity with SEQ ID NO: 1 or SEQ ID NO: 2, or variants or fragments thereof, in particular a peptidomimetic having the capability to interact at least with: neutrophils and/or neutrophil granules, and/or lactoferrin, and/or globet-cells and/or Muc2 proteins, and/or mucus and/or airway sputum. The peptidomimetic may have the capacity to adopt a multimeric, especially a trimeric, organization, and can be labelled, or associated with a reporter or a carrier entity, or associated with an active molecule. The invention also relates to a Solid-Phase Synthesis method for synthesizing a peptidomimetic of the invention, compositions comprising the same and use of the peptidomimetics as a medicamentor an inflammation marker or a neutrophilic inflammation marker.Type: GrantFiled: December 11, 2018Date of Patent: October 18, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEURInventors: Benoit Sebastien Marteyn, Yves-Marie Coic, Francoise Baleux
-
Patent number: 11460467Abstract: The present invention relates to an in vitro method for diagnosing lupus in a subject, said method comprising the step of detecting in a biological sample obtained from the subject the autoantibody recognizing the protein biomarker THEX1. More, the invention relates to kits and array useful for carrying out diagnosis methods according to the present invention.Type: GrantFiled: February 7, 2019Date of Patent: October 4, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université d'Aix Marseille, GFRS (Groupe Francophone de Recherche sur la Sclerodermie Systemique)Inventors: Nathalie Lambert, Fanny Arnoux, Doua Azzouz
-
Patent number: 11458118Abstract: Activating transcription factor 6 (ATF6) is involved in cystic fibrosis transmembrane conductance regulator (CFTR) repression and understanding this inhibitory mechanism is of great interest to develop a therapeutic approach based on UPR regulation. Using site-1 protease (S1P) inhibitor (e.g. PF-429242) the inventors showed that both membrane localization and function of F508del-CFTR are partially restored. Accordingly, the present invention relates to a method of treating a disease associated with reduced CFTR function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a S1P inhibitor.Type: GrantFiled: April 20, 2018Date of Patent: October 4, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE BRETAGNE OCCIDENTALE, ETABLISSEMENT FRANÇAIS DU SANG (EFS), CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BRESTInventors: Pascal Trouve, Claude Ferec, Mathieu Kerbiriou, Florentin Huguet
-
Patent number: 11458194Abstract: The inventors have developed a metastatic 4T1 breast tumor model in BALB/c mice. They have shown that the vaccination with xenogeneic embryonic stem cells in combination with valproic acid (VPA) generates a higher anti-tumoral response against breast cancer and inhibits metastasis development. They established that these responses are achieved only by the addition of valproic acid in the therapeutic regimen in comparison to the use ESCs or iPSCs alone. Thus, the inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to i) a population of pluripotent cells and ii) a compound selected from a group which activates MHC expression, as a combined preparation for use in a method for treating a subject suffering from a cancer, comprising a step of administering simultaneously, separately or sequentially to said subject a therapeutically amount thereof.Type: GrantFiled: May 24, 2017Date of Patent: October 4, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), UNIVERSITE PARIS-SACLAY, UNIVERSITE PARIS CITEInventors: Frank Griscelli, Ali Turhan, Annelise Bennaceur Griscelli
-
Patent number: 11440906Abstract: The present disclosure relates to biguanide derivatives of formula (I) and their rearrangement products. The present disclosure also relates to the use of these compounds in a method for treating cancer, in particular melanoma.Type: GrantFiled: December 21, 2018Date of Patent: September 13, 2022Assignees: Centre National de la Recherche Scientifique, INSERM (Institut National de la Santé et de la Recherche Médicale), Université Côte d'AzurInventors: Rachid Benhida, Stephane Rocchi, Cyril Ronco, Emile Jaune, Oleksandr Grytsai, Nedra Tekaya